LSI Europe’s Post

Today is the first day of #AUGIS24 in Manchester. We are particularly excited to share the significant findings from two key studies on preventing parastomal hernias (PSH) using DynaMesh® - FEG Textiltechnik IPST. Study 1: Chimney Trial from Scandinavia Study Design: A multi-centre, randomised controlled trial assessed the effectiveness of DynaMesh®-IPST (IPST) in preventing parastomal hernias (PSH). Outcome Comparison: The trial showed no significant differences in operating time, hospital stay, or complication rates between the IPST and control groups. Clinical Results: At the 12-month follow-up, the PSH rate in the control group was more than 35% higher than in the mesh group. Ethical Consideration: Due to this significant difference, the trial was prematurely terminated, as continuing without offering mesh to all patients was considered unethical. Mesh Details: The DynaMesh® IPST used was IP072415F1 15cm x 15cm x 4cm, placed in the intraperitoneal space. Conclusion: The trial concluded that mesh significantly reduces the risk of PSH and is a viable preventive option. Visit the team at stand 13 if you would like more information. #Dynamesh #IPST

Glide to success with CEREGLIDE™ 71 with TruCourse™ Technology– the latest addition to the CERENOVUS Stroke Solutions™! This new catheter is informed by stroke science insights from our Neurothromboembolic Initiative (NTI) that includes robust research and clinical findings to seek and address unmet needs in #stroke: https://bit.ly/3HZmvk7

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation

Rx 𝗨𝗦𝗔𝗕𝗜𝗟𝗜𝗧𝗬 evaluation: Dr Francois Lignereux (Nantes, France) conducted the clinical trial about Rx he first handheld femtolaser instrument for capsulotomy 👉 https://bit.ly/3Qwxg26.   𝗨𝗦𝗔𝗕𝗜𝗟𝗜𝗧𝗬 was evaluated. On a 4-level scale, the investigator was asked to assess the handling of the device in the operating field: it was “very easy” for 𝟵𝟳.𝟰% of the patients operated. This highlights the practicality and ease of use of the Rx device in clinical setting.   Clinical trial results led to the CE-marking of Rx Instrument in December 2023.

Dr Lignereux (Nantes, France) has conducted the clinical trial about Rx he first handheld femtolaser instrument for capsulotomy. Access the article here 👉 https://bit.ly/3Qwxg26. Clinical trial results led to the CE-marking of Rx Instrument in December 2023. 𝗨𝘀𝗮𝗯𝗶𝗹𝗶𝘁𝘆 was evaluated through assessment of the investigator. On a 4-level scale, the investigator was asked to assess the handling of the device in the operating field: it was considered “very easy” for 𝟵𝟳.𝟰% of the patients operated on. This feedback underscores the practicality and ease of use of the Rx device in a clinical setting.

Why choose Dr. PRP USA Kit? Our comprehensive comparison reports speak volumes 📊. From Emcyte PurePRP® to Ycellbio, see how our kit stands out in delivering high-concentration and high-quality PRP. Unlock the power of PRP therapy and elevate your practice with Dr. PRP USA. Dive into our comparisons at - Dr. PRP vs. Emcyte: https://bit.ly/3US1C1X - Dr. PRP vs. Integrity Classic: https://bit.ly/3UUO8T2 - Dr. PRP vs. PRP Kits: https://bit.ly/49VXhPH - Dr. PRP vs. Ycellbio: https://bit.ly/3P1PmIj

💓Boston Scientific’s WATCHMAN FLX device yields positive results in OPTION trial The finding is part of the three-year results from the global clinical trial, which evaluated the WATCHMAN FLX LAAC device for reducing stroke risk in patients with non-valvular atrial fibrillation after cardiac ablation. The results, presented at the American Heart Association’s Scientific Sessions 2024 and published in The New England Journal of Medicine, indicate the device’s effectiveness in reducing bleeding risks compared to first-line oral anticoagulation (OAC) therapies. The OPTION trial assessed the WATCHMAN FLX device against OAC, including direct oral anticoagulants (DOACs) and warfarin, in a study involving 1,600 patients across 114 sites in the US, Europe, and Australia. Read more online: https://lnkd.in/eZu4KRDw 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

NEVENT (#LSIEurope24 Innovator) was founded with a mission to eliminate patient harm caused by Retained Guidewires during the placement of vascular catheters using the Seldinger Technique. Each year, this medical error impacts over 1,500 patients, with a serious morbidity and mortality rate of 10.5%. Recognized by the Joint Commission as a Never Event in 2018, Retained Guidewires not only endanger lives but also inflict an additional $830 million in costs on physicians and healthcare systems each year. Current prevention strategies typically only identify such errors after they have occurred. In contrast, NEVENT has engineered the first effective device designed specifically to prevent the occurrence of guidewire retention. With a recent U.S. patent awarded in November 2023 and multiple international patents pending, NEVENT is at the forefront of enhancing patient safety. The company is also set to submit its NIH Grant proposal later this fall. We’re excited to announce that Anesthesiologist and Inventor, Rhodel Dacanay has been selected to present NEVENT at LSI Europe ‘24 this September 16-20 in Sintra, Portugal.

Going to CRT - Cardiovascular Research Technologies? Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI will be presenting 30-day data from the DurAVR™ THV US Early Feasibility Study (EFS), and Rishi Puri will be presenting the latest DurAVR THV FIH study results and an analysis of the EFS data. Mark your calendars! #CRT2024 Can’t attend? Sign up for clinical data updates here: https://lnkd.in/gur9JPeX DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

The transformation of healthcare and the drive to enhance patient care can only be achieved through strong partnerships. The shared mission of Velatura Public Benefit Corporation & Spesana is changing the continuum of care for clinicians and patients. Improved prior authorization means faster time to diagnosis and faster time to treatment. #partnerships #precisionmedicine #priorauthorization #healthcare #transformation #hie #interoperability #patientcare #moleculardiagnostics